Results 31 to 40 of about 27,075 (224)

A Novel BRCA1 Pathogenic Variant in Tunisian Patient With High Grade Ovarian Cancer: Favorable Therapeutic Response to Olaparib. [PDF]

Cancer Rep (Hoboken)
ABSTRACT Background Ovarian cancer is one of the leading causes of death from gynecological cancer worldwide. Genetic mutations in genes involved in key cellular functions such as BRCA1/2 play a central role in tumorigenesis and have major implications for targeted therapeutic strategies, especially the use of poly (ADP‐ribose) polymerase (PARP ...
Ammous-Boukhris N, Abdelmaksoud-Dammak R, Feki A, Khemiri S, Charfi S, Sallemi-Boudawara T, Daoud J, Khanfir A, Gargouri RM.   +8 more
europepmc   +2 more sources

MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC

Journal of Hematology & Oncology, 2020
Background PARP inhibitors have been the most promising target drugs with widely proven benefits among ovarian cancer patients. Although platinum-response, HR-related genes, or HRD genomic scar detection are acceptably used in assessment of Olaparib ...
Chenggong Sun, Wenyu Cao, Chunping Qiu, Chengcheng Li, Samina Dongol, Zhiwei Zhang, Ruifen Dong, Kun Song, Xingsheng Yang, Qing Zhang, Beihua Kong   +10 more
doaj   +1 more source

Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells

BMC Cancer, 2021
Background The advances in colorectal cancer (CRC) treatment include the identification of deficiencies in Mismatch Repair (MMR) pathway to predict the benefit of adjuvant 5-fluorouracil (5-FU) and oxaliplatin for stage II CRC and immunotherapy ...
Helena de Castro e Gloria, Laura Jesuíno Nogueira, Patrícia Bencke Grudzinski, Paola Victória da Costa Ghignatti, Temenouga Nikolova Guecheva, Natalia Motta Leguisamo, Jenifer Saffi   +6 more
doaj   +1 more source

Effects of the PARP Inhibitor Olaparib on the Response of Human Peripheral Blood Leukocytes to Bacterial Challenge or Oxidative Stress

Biomolecules, 2022
Prior studies demonstrate the activation of poly-(ADP-ribose) polymerase 1 (PARP1) in various pathophysiological conditions, including sepsis. We have assessed the effect of olaparib, a clinically used PARP1 inhibitor, on the responses of human ...
Sidneia Sousa Santos, Milena Karina Coló Brunialti, Larissa de Oliveira Cavalcanti Peres Rodrigues, Ana Maria Alvim Liberatore, Ivan Hong Jun Koh, Vanessa Martins, Francisco Garcia Soriano, Csaba Szabo, Reinaldo Salomão   +8 more
doaj   +1 more source

Correlation between molar activity, injection mass and uptake of the PARP targeting radiotracer [18F]olaparib in mouse models of glioma

EJNMMI Research, 2022
Purpose Radiopharmaceuticals targeting poly(ADP-ribose) polymerase (PARP) have emerged as promising agents for cancer diagnosis and therapy. PARP enzymes are expressed in both cancerous and normal tissue.
Chung Ying Chan, Samantha L. Hopkins, Florian Guibbal, Anna Pacelli, Julia Baguña Torres, Michael Mosley, Doreen Lau, Patrick Isenegger, Zijun Chen, Thomas C. Wilson, Gemma Dias, Rebekka Hueting, Véronique Gouverneur, Bart Cornelissen   +13 more
doaj   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial

Nature Communications
SOLACE2 (ACTRN12618000686202) investigates whether 12-weeks of olaparib, or cyclophosphamide-olaparib priming, improves subsequent durvalumab-olaparib progression-free survival (PFS), and is superior to olaparib monotherapy without any priming, in ...
Chee Khoon Lee, Apriliana E. R. Kartikasari, Nirashaa T. Bound, Katherine E. Francis, Kristy Shield-Artin, Justin Bedo, Ksenija Nesic, Katrina Diamante, Rachel L. O’Connell, Mutsa Madondo, Momodou Cox, Claire Davies, Cyril Deceneux, Georgia Goodchild, Andrew Jarratt, Emily Cassar, Hina Amer, U. G. Imalki U. Kariyawasam, Yeh Chen Lee, Janine Lombard, Sally Baron-Hay, Yoland Antill, Catherine Shannon, Sudarshan Selva-Nayagam, Philip Beale, Danka Zebic, Sandy Simon, Anneliese Linaker, Michael A. Quinn, Anthony T. Papenfuss, Matthew J. Wakefield, Cassandra J. Vandenberg, Michael Friedlander, Clare L. Scott, Magdalena Plebanski   +34 more
doaj   +1 more source

Development and Evaluation of Self-Microemulsifying Drug Delivery System for Improving Oral Absorption of Poorly Water-Soluble Olaparib

Pharmaceutics, 2023
The purpose of this study is to develop and evaluate a self-microemulsifying drug delivery system (SMEDDS) to improve the oral absorption of poorly water-soluble olaparib.
Yong-Han Kim, Seong-Bo Kim, Se-Hee Choi, Thi-Thao-Linh Nguyen, Sung-Hoon Ahn, Kyung-Sun Moon, Kwan-Hyung Cho, Tae-Yong Sim, Eun-Ji Heo, Sung Tae Kim, Hyun-Suk Jung, Jun-Pil Jee, Han-Gon Choi, Dong-Jin Jang   +13 more
doaj   +1 more source

VEGF inhibitor-induced vascular dysfunction involves redox-sensitive PARP activation and SIRT1 disruption. [PDF]

Exp Physiol
Abstract Vascular endothelial growth factor receptor (VEGFR) inhibitors are effective antiangiogenic agents used in cancer therapy. However, they are associated with cardiovascular disease, including hypertension and vascular dysfunction. The molecular mechanisms underlying these cardiovascular toxicities are unclear, but oxidative stress might be ...
Neves KB, Alves-Lopes R, Montezano AC, Touyz RM.   +3 more
europepmc   +2 more sources

Profile of olaparib in the treatment of advanced ovarian cancer [PDF]

, 2016
Dana M Chase,1,2 Shreya Patel,2,3 Kristin Shields4 1Division of Gynecologic Oncology, The University of Arizona Cancer Center, 2Division of Gynecologic Oncology, 3Creighton University School of Medicine, St Joseph’s Hospital and Medical Center ...
Chase DM, Shields K, Patel S
core